Reference
Undreiner L, et al. Betibeglogene Autotemcel GENE Therapy (BETI-CEL) Is Cost-Effective Versus Standard of Care in Patients with Transfusion-Dependent B-Thalassemia (TDT) in France. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PBI16, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/108183
Rights and permissions
About this article
Cite this article
Betibeglogene autotemcel gene therapy cost effective in transfusion-dependent β-thalassaemia in France. PharmacoEcon Outcomes News 868, 5 (2020). https://doi.org/10.1007/s40274-020-7337-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7337-9